We all know the concerned look in a patient's eyes as he or she asks, "Are all these seizures damaging my brain?" It doesn't take much to understand where this question is coming from. Patients experience firsthand the consequences of uncontrolled epilepsy: Days after a convulsion, they still struggle with concentration difficulties, exhaustion, and cognitive dysfunction. We tell them that these challenges are "normal after a big seizure" and explain how the brain needs time to recover from the electrical and chemical havoc wreaked by an epileptic event. The patients (or their families) then observe the gradual decline in memory or other cognitive functions incurred after years of epilepsy and naturally deduce that the cumulative effect of many seizures is to blame: After all, we've just spent time convincing them to blame one seizure from days ago for how bad they are feeling now. How can we then expect them to accept the possibility that a life of seizures is NOT damaging their brain? The article at hand by Rossini et al. makes exactly that argument in a very specific type of epilepsy: neocortical epilepsy caused by Type II focal cortical dysplasia (FCD). Let's review the evidence.
In Rossini et al., the authors took advantage of elegant invasive EEG technology (stereo-EEG or electrocorticography) to specifically evaluate immunohistological evidence of neuronal cell loss in brain regions of ictal onset versus early ictal spread and nonepileptic brain regions in a selected group of 20 patients with well-characterized focal neocortical epilepsy. They found that markers of tissue damage-neuronal paucity, extended gliosis, presence of inflammatory molecules/cells, and protein extravasation-were detectable in the lesional FCD area, particularly in the FCD-IIb subtype, but were not observed in the adjacent perilesional/nonlesional areas or in cryptogenic epileptic tissue obtained from epileptic patients with normal brain imaging and no pathological confirmation of an epileptic substrate. They concluded that injury biomarker expression is an intrinsic feature of the focal cortical malformation but not triggered by chronic seizure activity per se, appropriately stressing that such a conclusion can be potentially drawn only in the select patient population analyzed in their study, that is, patients with neocortical cryptogenic epilepsy or with FCD. These implications are intriguing, and the unquestionable value of this study lies more in the questions it raises rather than the answers it provides.
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Do Seizures Induce Brain Tissue Loss?
epileptic network, for example, hippocampal sclerosis. The observation that the cortex immediately surrounding a balloon cell dysplasia exhibits no neuronal cell loss does not necessarily imply that distant nodes involved in ictal spread should behave the same, nor does it eliminate the fact that hippocampal cell loss is induced by repetitive seizures (1) .
Second, accepting that neuronal cell loss occurs in patients with chronic epilepsy, have we settled whether it is due to the epileptic substrate itself, or due to the damaging effects of seizures? The findings of Rossini et al. should make us think twice before jumping to the conclusion that seizures are the exclusive contributor to neuronal cell loss in FCD type IIb, yet there is still a significant body of literature suggesting a link between seizure frequency and brain atrophy in most epilepsies. A recent meta-analysis on progressive atrophy in intractable temporal lobe epilepsy (2) found a pooled effect size of r = −0.42 for ipsilateral hippocampal atrophy related to epilepsy duration (95% confidence interval [CI] −0.51 to −0.32; p < 0.0001; I 2 = 65.22%) and r = −0.35 related to seizure frequency (95% CI −0.47 to −0.22; p < 0.0001; I 2 = 61.97%), with more than 80% of articles reporting duration-related progressive atrophy in extratemporal cortical and subcortical regions. It is interesting to note that in Rossini et al., there was a clear difference in age at epilepsy onset in the FCD groups-earlier in patients with FCD IIb (the group exhibiting clear evidence of neuronal cell loss) compared to FCD-IIa (5.2 vs 10.6 years, respectively). The implication of that difference on the study findings is unclear.
Third, the relationship between the study findings and surgical seizure outcomes deserves closer consideration. In the study group, 10/11 (91%) patients with FCD IIb were rendered seizure-free with surgery, as opposed to 3/5 (60%) with FCD IIa and 2/4 (50%) with cryptogenic epilepsy. The study sample size is small, but it would have been interesting to see if the findings remain unchanged when only seizure-free patients (i.e., those with unquestionably accurately localized epileptogenic zone) are analyzed. Such exploration would be of particular interest considering the literature on poorer seizure outcomes after long epilepsy duration in patients with frontal lobe epilepsy, even with subgroup analyses focusing on FCD cases (3) .
In an evolving epilepsy surgery landscape with FCD representing an increasingly larger proportion of our surgical patients (4), along with a culture of epilepsy care pushing towards a more inclusive and comprehensive understanding of cognitive and psychosocial outcomes (5), it is critical to gain a better grasp on the relationships between epileptic substrate, seizures, and behavior/cognition. Careful studies-such as the one highlighted here-will get us closer to that understanding.
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